endocrine system disease: A disease involving the endocrine system.
Disorders of endocrine glands in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
E4_ENDINOTH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
65 |
4. Check minimum number of eventsNone |
65 |
5. Include endpointsNone |
65 |
6. Filter based on genotype QC (FinnGen only) |
62 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Morbositates glandularum endocrinarum in morbis alibi classificatis
Similar endpoints
↥List of similar endpoints to
Disorders of endocrine glands in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Other endocrine disorders
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 359 | 201 | 156 |
| Only index persons | 303 | 172 | 131 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 48.72 | 48.00 | 49.57 |
| Only index persons | 47.76 | 46.75 | 49.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 62 | 33 | 29 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 50.40 | 51.56 | 49.08 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 65
- Matched controls
- 650
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H01AC01
ATC
somatropin; parenteral
+∞
18.6
17
*
H02AB09
ATC
hydrocortisone; systemic
32.3
17.0
22
10
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
8.2
15.6
29
58
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
47.7
12.8
15
*
127
Kela drug reimbursment
Transplant complication
58.4
12.4
14
*
XF400
NOMESCO Finland
ECG with 12 standard connections
7.0
12.4
25
53
E35.8
ICD-10 Finland
Disorders of other endocrine glands in diseases classified elsewhere
+∞
11.8
11
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
16.2
11.8
19
16
Z94.0
ICD-10 Finland
Kidney transplant status
72.3
11.0
12
*
ZX120
NOMESCO Finland
Intravenous
9.8
10.5
22
32
H02AB04
ATC
methylprednisolone; systemic
6.4
10.1
21
45
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
65.1
10.0
11
*
L04AX01
ATC
azathioprine; systemic
21.8
9.9
14
8
A11CC03
ATC
alfacalcidol; systemic
26.5
9.8
13
6
602
Kela drug reimbursment
Children's severe malnutrition
36.1
9.8
12
*
L04AD02
ATC
tacrolimus; systemic
116.2
9.7
10
*
205
Kela drug reimbursment
Chronic hypertension
5.4
9.7
27
76
ZXE20
NOMESCO Finland
More than three and less than five hours
8.9
9.5
21
33
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
8.3
8.8
20
33
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.4
8.7
22
56
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
102.8
8.6
9
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
8.5
8
*
301
Kela drug reimbursment
Growth hormone
+∞
8.5
8
*
E35.0
ICD-10 Finland
Disorders of thyroid gland in diseases classified elsewhere
+∞
8.5
8
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.1
8.4
23
63
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
38.7
8.3
10
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
26.0
8.3
11
5
ZXE10
NOMESCO Finland
More than one and less than three hours
4.5
8.3
36
141
L04AA01
ATC
[U] ciclosporin
51.4
7.9
9
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
21.6
7.9
11
6
TPH04
NOMESCO Finland
Cathetrisation of vein
4.7
7.8
24
72
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
89.9
7.6
8
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.8
7.6
16
23
WX408
NOMESCO Finland
General anesthesy, balanced
4.3
7.5
30
109
Z99.2
ICD-10 Finland
Dependence on renal dialysis
+∞
7.4
7
*
E35.1
ICD-10 Finland
Disorders of adrenal glands in diseases classified elsewhere
+∞
7.4
7
*
B05DA
ATC
Isotonic solutions
+∞
7.4
7
*
Z49.2
ICD-10 Finland
Other dialysis
+∞
7.4
7
*
E34.39
ICD-10 Finland
Short stature, not elsewhere classified
+∞
7.4
7
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
7.4
7
*
L04AA06
ATC
mycophenolic acid; systemic
23.2
7.4
10
5
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
23.2
7.4
10
5
N18.8
ICD-10 Finland
Other chronic renal failure
23.2
7.4
10
5
A12AA04
ATC
calcium carbonate; oral
34.2
7.4
9
*
TK800
NOMESCO Finland
Hemodialysis
34.2
7.4
9
*
K03.66
ICD-10 Finland
Tooth plaque
5.3
7.1
17
41
K00.40
ICD-10 Finland
Postnatal enamel hypoplasia
14.4
6.9
11
9
A41.9
ICD-10 Finland
Sepsis, unspecified
14.4
6.9
11
9
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.6
6.8
20
57
C03CA01
ATC
furosemide; systemic
4.0
6.7
27
98
137
Kela drug reimbursment
Uraemia requiring dialysis
77.1
6.6
7
*
Z2446
NOMESCO Finland
Social worker
4.9
6.5
17
44
7143C
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[POLYARTHRITIS JUVENILIS SERONEGATIVA]
+∞
6.3
6
*
B05DB
ATC
Hypertonic solutions
+∞
6.3
6
*
186
Kela drug reimbursment
Growth retardation associated with renal failure (growth hormone)
+∞
6.3
6
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.7
6.1
17
46
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.7
6.1
17
46
I35.0
ICD-10 Finland
Aortic (valve) stenosis
12.8
6.0
10
9
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
12.8
6.0
10
9
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
78
4.02
6.18
45.7
7.3
1.26
1.19
mmol/l
0.57
23
71
12
18
7.90
5.56
2.8
1.8
5.38
8.25
u/l
0.37
12
13
16
46
4.29
5.29
3.6
2.0
—
—
—
0
0
38
195
3.28
5.23
31.4
11.1
1.33
1.30
inr
—
10
55
11
16
8.02
5.21
2.8
1.9
17.18
13.93
iu/l
—
11
10
8
7
12.79
4.93
1.3
1.3
—
—
—
0
0
15
45
4.03
4.66
3.7
2.0
—
—
—
0
0
8
8
11.18
4.66
3.1
4.3
51.63
51.13
%
—
8
8
9
12
8.49
4.52
1.9
1.3
—
—
—
0
0
11
20
6.39
4.52
3.6
1.4
—
—
—
0
0
11
20
6.39
4.52
3.7
5.4
96.73
98.60
%
0.09
11
20
26
115
3.10
4.47
4.0
2.4
—
—
—
0
0
19
70
3.42
4.39
3.2
2.0
—
—
—
0
0
7
6
12.85
4.38
1.6
2.7
—
—
—
0
0
7
6
12.85
4.38
1.6
2.7
—
—
—
0
0
19
71
3.37
4.28
25.1
5.6
0.82
0.79
mmol/l
0.42
19
66
8
10
8.93
4.19
115.1
2.7
22.69
23.49
mmol/l
—
8
10
15
49
3.68
4.12
48.3
7.0
4.83
4.81
kpa
0.07
15
44
7
7
11.01
4.11
2.4
5.9
—
—
—
0
0
7
7
11.01
4.11
1.7
1.6
—
—
—
0
0
12
28
5.01
4.07
20.4
3.4
1.23
1.24
mmol/l
0.30
12
21
22
93
3.06
4.04
5.5
3.5
1.45
0.68
e6/l
0.41
17
56
8
11
8.10
3.99
2.6
1.6
—
—
—
0
0
9
15
6.77
3.97
4.6
6.2
170.56
160.80
%
—
9
15
21
88
3.05
3.90
5.9
3.7
7.99
1.20
e6/l
0.77
16
51
15
51
3.52
3.87
31.9
13.9
24.13
25.08
mmol/l
0.67
15
51
25
116
2.88
3.87
13.3
3.4
1.01
1.02
kg/l
—
8
19
7
8
9.62
3.87
2.4
5.4
7.57
10.75
%
—
7
8
19
76
3.12
3.81
16.1
2.2
11.66
12.78
umol/l
0.37
19
69
30
155
2.74
3.78
9.3
3.5
27.37
28.10
u/l
0.12
30
144
32
171
2.72
3.78
17.0
3.8
—
—
—
0
0
7
9
8.54
3.65
1.7
2.3
—
—
—
0
0
7
9
8.54
3.65
1.7
2.3
—
—
—
0
0
39
233
2.68
3.65
13.1
3.7
0.00
0.03
estimate
—
9
35
39
234
2.67
3.60
16.1
5.1
0.00
0.00
estimate
—
9
33
39
235
2.65
3.56
13.1
3.7
0.00
0.00
estimate
—
8
31
44
282
2.73
3.53
12.1
5.0
6.18
6.59
mmol/l
0.72
44
264
6
7
9.28
3.33
1.5
6.0
29.00
34.14
%
—
6
7
51
361
2.92
3.23
17.2
7.1
100.88
92.79
u/l
0.33
51
332
47
322
2.66
3.13
18.6
4.2
7.00
112.40
e6/l
—
6
5
9
21
4.80
3.13
4.3
1.6
—
—
—
0
0
6
8
8.11
3.12
1.5
1.9
—
—
—
0
0
7
12
6.38
3.11
1.7
2.0
—
—
—
0
0
23
114
2.57
3.05
6.6
3.5
311.00
9863.73
umol/l
0.76
23
93
13
47
3.21
3.02
10.3
9.5
103.23
104.72
mmol/l
0.29
13
47
9
22
4.57
3.01
1.1
1.7
—
—
—
0
0
9
22
4.57
3.01
1.1
1.7
—
—
—
0
0
37
232
2.38
2.91
10.2
6.8
8.27
10.72
umol/l
2.03
37
217
9
23
4.37
2.90
2.8
2.2
—
—
—
0
0
8
18
4.91
2.90
3.4
1.3
—
—
—
0
0
35
216
2.34
2.84
38.8
7.9
1.22
1.22
mmol/l
0.09
35
192
7
14
5.46
2.81
2.0
1.9
—
—
—
0
0
36
226
2.33
2.79
4.5
2.6
—
—
—
0
0
8
19
4.64
2.78
1.1
1.6
—
—
—
0
0
23
119
2.44
2.75
17.0
3.9
0.00
0.00
estimate
—
9
31
52
386
2.74
2.74
7.5
3.8
15.37
14.67
pmol/l
1.22
47
340
6
11
5.88
2.60
2.3
1.7
—
—
—
0
0
5
8
6.65
2.41
1.4
1.5
—
—
—
0
0
10
34
3.29
2.40
10.4
3.1
—
—
—
0
0
6
13
4.96
2.33
2.5
3.0
—
—
—
0
0
28
174
2.07
2.08
15.0
3.6
—
—
—
0
0
7
21
3.60
2.03
4.0
1.4
397.14
347.29
mu/l
—
7
21
5
11
4.82
1.98
1.0
1.0
2.86
3.01
g/l
—
5
11
5
12
4.41
1.86
1.0
1.3
—
—
—
0
0
5
12
4.41
1.86
1.0
1.0
6.78
7.69
g/l
—
5
12
5
12
4.41
1.86
1.0
1.0
3.94
3.91
g/l
—
5
12
5
12
4.41
1.86
1.0
1.0
—
—
—
0
0
9
36
2.74
1.82
1.2
1.7
—
—
—
0
0
7
24
3.14
1.78
1.6
1.3
—
—
—
0
0
6
19
3.37
1.70
1.0
1.2
—
—
—
0
0
6
22
2.90
1.47
1.0
1.2
—
—
—
0
0
6
22
2.90
1.47
18.3
11.0
0.50
0.70
%
—
6
22
22
140
1.86
1.45
2.1
1.9
—
—
—
0
0
0
41
0.00
1.36
0.0
1.6
—
—
—
0
0
50
420
1.83
1.20
31.5
12.0
86.38
85.60
ml/min/173m2
0.05
37
324
5
20
2.62
1.17
1.8
1.4
—
—
—
0
0
5
22
2.37
1.05
1.4
1.3
—
—
—
0
0
57
513
1.90
0.97
48.0
15.1
106.98
71.37
umol/l
1.16
57
513
17
113
1.68
0.94
8.4
3.1
1835.72
1670.00
ng/l
0.08
17
97
36
297
1.48
0.76
9.9
3.1
51.14
46.97
u/l
0.11
36
279
5
27
1.92
0.70
5.8
7.9
0.62
1.23
%
—
5
27
5
27
1.92
0.70
5.8
7.8
0.68
0.69
%
—
5
27
8
50
1.68
0.64
3.3
2.5
110.62
29.83
u/l
—
8
42
22
170
1.44
0.63
4.3
3.0
29.07
26.88
ng/l
0.09
16
107
57
530
1.61
0.51
25.6
10.1
24.34
25.74
u/l
0.23
57
506
33
376
0.75
0.48
4.3
3.6
—
—
—
0
0
12
88
1.45
0.44
1.3
1.3
10.33
35.94
iu/ml
—
6
27
0
15
0.00
0.42
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
147.40
—
0
5
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
21.82
—
0
5
59
571
1.36
0.16
65.2
19.7
37.92
39.98
%
1.35
52
539
18
167
1.11
0.08
1.5
1.8
109.50
100.67
pmol/l
—
6
80
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
102.25
—
0
8
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
2.11
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
55
0.90
-0.00
5.8
6.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1710.00
—
0
5
6
65
0.92
-0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
213.00
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint E4_ENDINOTH and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ENDINOTH | 2.635 [1.58, 4.39] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.016 |
During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 142 males with E4_ENDINOTH died.
Mortality risk
Mortality risk for people of age
years, who have E4_ENDINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.513% |
| 5 | No data | 3.446% |
| 10 | No data | 8.439% |
| 15 | No data | 15.679% |
| 20 | No data | 25.275% |
Relationships between endpoints
↥Index endpoint: E4_ENDINOTH – Disorders of endocrine glands in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data